DVAX

Dynavax Technologies Corporation Press Releases

$14.51
*  
0.19
1.33%
Get DVAX Alerts
*Delayed - data as of Nov. 20, 2014  -  Find a broker to begin trading DVAX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    DVAX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)
11/10/2014 6:00:00 AM - Market Wire
▼-6.39 % Price Change since this news event. The Volume Ratio is 0.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Dynavax Announces One-for-Ten Reverse Stock Split
11/7/2014 5:05:00 PM - Market Wire


Dynavax Announces One-for-Ten Reverse Stock Split
11/7/2014 5:05:00 PM - Market Wire
▼-13.11 % Price Change since this news event. The Volume Ratio is 0.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Dynavax Reports Third Quarter 2014 Financial Results
11/5/2014 6:00:00 AM - Market Wire
▲806.88 % Price Change since this news event. The Volume Ratio is 1.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
10/13/2014 6:00:00 AM - Market Wire
▲951.45 % Price Change since this news event. The Volume Ratio is 1.24.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Dynavax Announces Resignation of Dino Dina From Board of Directors
10/7/2014 4:00:00 PM - Market Wire


Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B(TM)
9/22/2014 6:00:00 AM - Market Wire